top of page
Abstract Blue Light_edited.jpg

China Market Entry and Market Access: Go / No-Go Decisions for Pharma, Biotech and Medtech

SILREAL helps Western life-sciences leadership decide whether, when and how to enter or expand in China. We assess policy, regulatory pathways, reimbursement, procurement and partner risk before capital is committed. The outcome is a go / no-go decision with the evidence gaps, commercial assumptions and conditions for proceeding stated.

Our Expertise

​We help life science and healthcare companies enter new markets with tailored go-to-market strategies, competitive insights, and regulatory alignment that drive sustainable growth.

China Market Entry Strategy

  • Unmet-need analysis & competitive mapping

  • Phased go-to-market roadmaps + KPI dashboards

Location Analysis & Risk Mitigation

  • Benchmarking of China’s innovation hubs (Beijing, Shanghai, Shenzhen, Suzhou)

  • Regulatory, IP, supply-chain and reimbursement risk scoring

Partner Search & Localization

  • Shortlisting & due-diligence of distributors, CMOs, CROs, hospitals

  • Tech-transfer and licensing support for compliant scale-up

Strategic Delegation Trips

  • Curating C-suite visits and policy roundtables to accelerate stakeholder trust

  • Post-trip action plans and follow-up facilitation

Our Expertise

​We help life science and healthcare companies enter new markets with tailored go-to-market strategies, competitive insights, and regulatory alignment that drive sustainable growth.

China Market Entry Strategy

  • Unmet-need analysis & competitive mapping

  • Phased go-to-market roadmaps + KPI dashboards

Location Analysis & Risk Mitigation

  • Benchmarking of China’s innovation hubs (Beijing, Shanghai, Shenzhen, Suzhou)

  • Regulatory, IP, supply-chain and reimbursement risk scoring

Partner Search & Localization

  • Shortlisting & due-diligence of distributors, CMOs, CROs, hospitals

  • Tech-transfer and licensing support for compliant scale-up

Strategic Delegation Trips

  • Curating C-suite visits and policy roundtables to accelerate stakeholder trust

  • Post-trip action plans and follow-up facilitation

Why SILREAL?

Strategic Market Entry Expertise

SILREAL develops tailored go-to-market strategies that address regulatory pathways, reimbursement dynamics, and competitive positioning. We ensure that clients enter China and Europe with clarity, speed, and long-term growth alignment.

In-Depth Market Intelligence

Through comprehensive market and competitor analysis, patient insights, and stakeholder mapping, SILREAL provides the evidence base for confident decision-making. Our data-driven approach minimizes risks and maximizes opportunities.

Documented mandates

The China market strategy for ESA Grimma's hospital segment and the Nantong location analysis for a Saarland innovation hub are documented in the case studies below.

Why SILREAL?

Strategic Market Entry Expertise

SILREAL develops tailored go-to-market strategies that address regulatory pathways, reimbursement dynamics, and competitive positioning. We ensure that clients enter China and Europe with clarity, speed, and long-term growth alignment.

In-Depth Market Intelligence

Through comprehensive market and competitor analysis, patient insights, and stakeholder mapping, SILREAL provides the evidence base for confident decision-making. Our data-driven approach minimizes risks and maximizes opportunities.

Documented mandates

The China market strategy for ESA Grimma's hospital segment and the Nantong location analysis for a Saarland innovation hub are documented in the case studies below.

Related Case Studies

China Market Entry and Partner Access: Champions Oncology

China Reimbursement Analysis for the German Healthcare Export Initiative

Operational Excellence Through Healthcare Digitalization in Germany

Pharma Compliance Consulting: Digital Quality Management and SOP Optimization for a Global CDMO

Germany–China Policy Exchange on COPD for AstraZeneca

Location Analysis of Nantong (China) for an Innovation Hub of Saarland

Digital Brand Equity Study on the Chinese Headphone Market for Sonova

Building Digital-Health Policy Bridges: German Federal Ministry of Health Delegation to China

Strategic Advisory for French Private Equity Investment in German Healthcare Product Market​

​Expanding German Engineering into China’s Healthcare Market:
ESA Grimma’s Hospital Segment Transformation

A cross-border decision in progress?

We can determine whether a formal assessment, execution mandate or ongoing executive advisory is justified.

bottom of page